✦ LIBER ✦

Is axitinib the preferred second-line agent for renal cell carcinoma?

✍ Scribed by Bradford R. Hirsch; Daniel J. George

Book ID: 119219282
Publisher: Frontline Medical Communications, Inc.
Year: 2012
Tongue: English
Weight: 83 KB
Volume: 9
Category: Article
ISSN: 1548-5315
DOI: 10.1016/j.cmonc.2012.07.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Axitinib and sorafenib in second-line tr

Axitinib and sorafenib in second-line treatment of advanced renal cell carcinoma

✍ Jame Abraham 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 85 KB

Second-line therapy for refractory renal

Second-line therapy for refractory renal-cell carcinoma

✍ Fable Zustovich; Giuseppe Lombardi; Ornella Nicoletto; Davide Pastorelli 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 285 KB

81 Updated results of the phase 3 AXIS t

81 Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)

✍ B. Escudier; B.I. Rini; T.E. Hutson; M. Gore; S. Oudard; J. Tarazi; B. Rosbrook; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 70 KB

New antiangiogenic agent for renal-cell

New antiangiogenic agent for renal-cell carcinoma

✍ Brad Timms 📂 Article 📅 2002 🏛 The Lancet 🌐 English ⚖ 59 KB

The Chromophobe Tumor Grading System is

The Chromophobe Tumor Grading System is the Preferred Grading Scheme for Chromophobe Renal Cell Carcinoma

✍ Finley, David S.; Shuch, Brian; Said, Jonathan W.; Galliano, Gretchen; Jeffries, 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 710 KB

Second-line strategies for metastatic re

Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches

✍ A. J. Schrader; Z. Varga; A. Hegele; S. Pfoertner; P. Olbert; R. Hofmann 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 376 KB